… observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joi...
Results for “Oriel Therapeutics”
Search across the indexed text of every released document.
Names that match “Oriel Therapeutics”
46 documents found
Sprout Capital IX, L.P. (Healthcare Technology Portfolio) $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,],K,L,M and N in this Appendix. Gross Multiple Total Value Realized Unrealized Value Value Total Cost Vintage Company Sector Year Portion) Gross...
Sprout Capital VIL, L.P. (Healthcare Technology Portfolio) $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,],K,L,M and N in this Appendix. Gross Multiple Gross Vintage Total Realized Unrealize Total (Realized Multiple Company Year Cost Value d Value Valu...
… observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joi...
molecular immunology at The Pasteur Institute and earned an M.D. and Ph.D. from the University of Paris, and an M.B.A. from Columbia University. Jeani Delagardelle, (57), Managing Director, helped found New Leaf in 2005. She joined Sprout in 2000. At New Leaf, Jeani leads the Me...
Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction types The New Leaf team is well positioned to continue to play a leadership role in the sector. Over the last two decades, the Fund Managers have demonstrated an ability to access high...
From: Steven Victor MD 111.11111..... Sent: 11/23/2012 1:06:38 PM To: CC: Subject: Report on Stem Cells future PUBLISHED: 22 NOVEMBER 2012 The view from the US: Stem cell therapy steps up a gear with first approval and improved political climate Special Report Peter Winter Positi...
Through its Common Fund the NIH has established the Center for Regenerative Medicine (NIH CRM), to support this field, with the goal of accelerating the translation of stem cell-based clinical therapies. State funding filling the void With stem cell research in general not attr...
ACKRELL CAPITAL Cannabis Investment Report | December 2017 Toronto Stock Exchange ($U.S. millions, except stock price) LTM Forward Forward EV Revenue EBITDA Stock % Below . : . Price 52-Week Market Enterprise LTM LTM Multiples __Muttiples Multiples Company Ticker 11/30/17 Hi...
Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new breakthrough therapy designation that can be granted to expedite th...
New Leaf has not created a formal advisory board for therapeutics
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%